Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

• Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi.

• French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing, or $470 million, plus $2.00 more per share in cash if Vigil’s Alzheimer’s drug achieves commercial sales.

• Vigil’s drug VG-3927 is a Phase 2-ready clinical candidate, it said.

Vigil Neuroscience (VIGL) shares jumped nearly 250% Thursday after the Alzheimer’s disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi (SNY).

Sanofi agreed to pay $8.00 per share in cash at closing, a significant premium over Vigil’s closing price of $2.31 on Wednesday, for a total of $470 million. The company will pay an additional $2.00 per share in cash if Vigil’s Alzheimer’s drug, VG-3927, achieves commercial sales, which would bring the total to $600 million. The deal is expected to close in the third quarter of 2025.

VG-3927 is a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease, Vigil said.

U.S.-listed shares of Sanofi edged lower in recent trading Thursday. The stock is up nearly 10% in 2025 so far.

Read the original article on Investopedia